The present invention relates to the field of the production, identification and selection of biological binding molecules such as antibodies or fragments thereof, as well as to their use in the therapy and prophylaxis of cancer diseases, such as, in particular, malignant B-cell neoplasia.
The binding molecules are able to selectively bind to autonomously active or autonomously activated B-cell receptors, the autonomously active or autonomously activated B-cell receptors being characterized by the presence of structural domains to which the binding molecule selectively binds and which are responsible for the autonomously active or autonomously activated state of the B-cell receptors.